Header

UZH-Logo

Maintenance Infos

Control of widespread hypertrophic lupus erythematosus with T-cell-directed biologic efalizumab


Navarini, A A; Kerl, K; French, L E; Trüeb, R M (2010). Control of widespread hypertrophic lupus erythematosus with T-cell-directed biologic efalizumab. Dermatology, 220(3):249-253.

Abstract

HLE features interface dermatitis and epidermal hyperplasia, which are both explainable by T-cell-mediated immunologic effects. Correspondingly, our case responded well to the treatment with efalizumab. While the withdrawal of efalizumab from the market leaves patients with psoriasis many other options for effective therapy, it disproportionately affects patients with T-cell-mediated orphan diseases like refractory HLE.

Abstract

HLE features interface dermatitis and epidermal hyperplasia, which are both explainable by T-cell-mediated immunologic effects. Correspondingly, our case responded well to the treatment with efalizumab. While the withdrawal of efalizumab from the market leaves patients with psoriasis many other options for effective therapy, it disproportionately affects patients with T-cell-mediated orphan diseases like refractory HLE.

Statistics

Citations

4 citations in Web of Science®
4 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

17 downloads since deposited on 07 Jan 2011
10 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2010
Deposited On:07 Jan 2011 17:56
Last Modified:01 Jul 2016 12:44
Publisher:Karger
ISSN:1018-8665
Publisher DOI:https://doi.org/10.1159/000277614
PubMed ID:20110637

Download

Preview Icon on Download
Preview
Content: Published Version
Filetype: PDF
Size: 408kB
View at publisher